Resonance Health Akcija

Resonance Health EBITDA

Vrijednost EBITDA (Заработак пре камата, пореза, амортизације и отписивања) od Resonance Health (RHT.AX) na dan 16. авг 2026. je -875.300,00 AUD. Prethodne godine, EBITDA (Заработак пре камата, пореза, амортизације и отписивања) je bio -167.300,00 AUD — promjena od 423,19% (niži).

EBITDA

-875.300,00AUD

YoY

423,19%

Zadnja ažuriranja:

EBITDA (Заработак пре камата, пореза, амортизације и отписивања) od Resonance Health je 2026 -875.300,00 AUD. EBITDA (Заработак пре камата, пореза, амортизације и отписивања) od Resonance Health je bio 2025 -167.300,00 AUD. Pad je time 423,19% niži u odnosu na prethodnu godinu.
Access this data via the Eulerpool API

Resonance Health Анализа акција

Šta radi Resonance Health? Resonance Health Ltd is an Australian company that operates in the medical technology industry. The company's business model is to offer groundbreaking solutions for the diagnosis and treatment of liver and iron diseases. As a pioneering company in the development of methods and technologies for quantifying liver and iron concentrations, Resonance Health continually sets new standards in the industry. The company was founded in 2000 by a team of biomedicine professionals from the University of Western Australia. Over the years, the company has gained a lot of experience and constantly evolved to keep up with the progress of medical technology. The goal is to provide patients with better treatment and improved quality of life. One division of the company is the development and manufacturing of diagnostic tools for quantifying liver and iron diseases such as hepatitis, fatty liver, or hemochromatosis. The quantification method used by Resonance Health is called FerriScan. This method is non-invasive and painless, using magnetic resonance imaging (MRI) to measure the concentration of iron in the tissue. This is particularly important as a change in iron content can indicate a progressing liver disease. In addition to the FerriScan diagnostic tool, Resonance Health also offers a software package for analyzing FerriScan results, which is used by physicians and clinicians to assess disease progression. Furthermore, the company also develops solutions in the field of hemochromatosis, a genetic disorder that can lead to increased iron levels in the body. Another division of Resonance Health is the provision of research and development services to further develop and improve FerriScan and other technologies. The company collaborates with other companies, scientific institutions, and universities to advance the current developments in liver and iron diagnostics. Resonance Health has a range of products that contribute to better diagnosis and treatment of liver and iron diseases. These include FerriScan, the FerriSmart software package for precise monitoring of iron and liver health, and Hepatica, a software supporting hospitals and clinics in the diagnosis of liver diseases. The company is an innovative leader in the industry, contributing to improving the quality of life for patients. The products and services of Resonance Health have helped doctors and clinicians to effectively treat and diagnose liver and iron diseases. Additionally, the company has established a strong scientific foundation and works closely with leading institutions to continuously develop innovative solutions. Resonance Health is a company with a rich history that continues to evolve to meet the demands of the medical technology industry. The company aims to continuously improve the diagnosis and treatment of liver and iron diseases and offer better solutions. Resonance Health je jedna od najpopularnijih kompanija na Eulerpool.

Često postavljena pitanja o akciji Resonance Health

EBITDA (Заработак пре камата, пореза, амортизације и отписивања) kompanije Resonance Health iznosi -875.300,00 AUD u 2026. godini.

EBITDA (Заработак пре камата, пореза, амортизације и отписивања) od Resonance Health se promijenio sa -167.300,00 AUD na -875.300,00 AUD, što predstavlja promjenu od 423,19%. Vrijednost je niži nego prethodne godine.

Na Eulerpool-u možete pronaći potpuni historijski razvoj EBITDA (Заработак пре камата, пореза, амортизације и отписивања) Resonance Health od 2006. — sa godišnjim vrijednostima, grafikonima i detaljnom analizom.

EBITDA мери оперативну перформансу пре утицаја финансијске структуре, окружења пореза и не-готовинских отписивања.

EBITDA = EBIT + Амортизација и отписивање

EBITDA (Заработак пре камата, пореза, амортизације и отписивања)'s AUD je ključan faktor za investitore. Promene u ovoj metrici mogu signalizirati poboljšane ili pogoršane fundamentalne faktore, direktno utiču na cenu akcije. Na Eulopoolu, možete pratiti EBITDA (Заработак пре камата, пореза, амортизације и отписивања)'s Resonance Health istorijski i u realnom vremenu.

Access this data via the Eulerpool API

Извештај о добити и губитку — Resonance Health

Sve ključne metrike — Resonance Health

Раст